A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. Th...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC neurology Ročník 18; číslo 1; s. 188 - 12
Hlavní autoři:	Camporeale, Angelo, Kudrow, David, Sides, Ryan, Wang, Shufang, Van Dycke, Annelies, Selzler, Katherine J., Stauffer, Virginia L.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 09.11.2018 BioMed Central Ltd Springer Nature B.V BMC
Témata:	Adolescent Adult Aged Analysis Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Calcitonin gene-related peptide CGRP Chronic illnesses Clinical trials Double-Blind Method Drug dosages Electrocardiography Female Galcanezumab Headache Headaches Humans Injection Laboratories Male Medicine Medicine & Public Health Middle Aged Migraine Migraine Disorders - drug therapy Monoclonal antibodies Neurochemistry Neurology Neurosurgery Nonsteroidal anti-inflammatory drugs Pain Patients Peptides Pharmaceutical industry Prevention Psychopharmacology Quality of life Questionnaires Research Article Respiratory tract diseases Rhinopharyngitis Safety Sinusitis Studies Suicides & suicide attempts Treatment Outcome Vital signs Young Adult United States United States > US Headache Galcanezumab CGRP Migraine
ISSN:	1471-2377, 1471-2377
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!